News | August 29, 2014

CardiacAssist Receives Health Canada Approval for Protek Duo Veno-Venous Cannula

August 29, 2014 — CardiacAssist announced it has received a Class 2 medical device license from Health Canada for its new Protek Duo veno-venous cannula. The Protek Duo is licensed for use as a single cannula for both venous drainage and reinfusion of blood via an internal jugular vein during extracorporeal life support procedures.

Approximately 18,000 people in Canada are diagnosed with acute respiratory distress syndrome (ARDS) every year. Despite receiving therapy with mechanical ventilation, which is widely considered the standard of care, almost half of those diagnosed with ARDS will die as a result of the disease. Veno-venous extracorporeal life support (VV ECLS) is an emerging therapy designed to provide a higher level of support by infusing oxygen directly into the blood using an oxygenator. In one large randomized, controlled clinical trial of 180 adult ARDS patients, the use of advanced VV ECLS therapy was shown to improve the rate of survival free of disability by 34 percent versus conventional management with mechanical ventilation.

The Protek Duo cannula is designed to address two major roadblocks that have previously kept VV ECLS therapy from becoming a new standard of care: the difficulty of initiating and maintaining a patient on VV ECLS support versus mechanical ventilation, and suboptimal gas exchange rates with currently available devices. Insertion of the Protek Duo cannula can be performed through a minimally invasive percutaneous procedure, and patient management is simplified by combining with the lightweight and compact TandemHeart pump, which can be placed directly on the patient. The TandemHeart platform recently received a Class 4 medical device license from Health Canada for up to 10 days of circulatory support and is designed to simplify patient ambulation and enable freedom of movement not possible with mechanical ventilation or any alternative ECLS device. Additionally, the Protek Duo cannula is designed for omnidirectional flow and can bypass the right ventricle of the heart by directing flow from the patient’s right atrium to the pulmonary artery, optimizing gas exchange and simultaneously reducing stress on the right side of the heart.

“The Canadian launch of the Protek Duo cannula is taking TandemHeart into new territory. We are now working on new innovations to help both heart and respiratory failure patients, with even more new products in the pipeline coming right behind Protek Duo. Our goal will be to keep respiratory patients moving while continuing our mission to advance the treatment of heart failure,” said John Marous, president and CEO of CardiacAssist.

For more information: www.cardiacassist.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init